Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
| Website: | www.insmed.com |
| Email: | blaine.davis@insmed.com |
| Main Phone: | +1 908 977-9900 |
| Address: | 10 Finderne Avenue |
| Address 2: | Building 10 |
| State: | NJ |
| City / Town: | Bridgewater |
| Country: | USA |
| Postal Code: | 08807 |
| Exchange: | NGS |
| CEO: | William Lewis |
| Employees: | 373 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
First drug granted approval under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (Image: Bronchiectasis News Today)
Gold and other precious metals are heading higher again and cementing their status as an ongoing safe haven in time of volatility. Samaranta Mining Corporation (SAX.TSXV) is doing its best to
Gathering Data... Please wait Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
| Website: | www.insmed.com |
| Email: | blaine.davis@insmed.com |
| Main Phone: | +1 908 977-9900 |
| Address: | 10 Finderne Avenue |
| Address 2: | Building 10 |
| State: | NJ |
| City / Town: | Bridgewater |
| Country: | USA |
| Postal Code: | 08807 |
| Exchange: | NGS |
| CEO: | William Lewis |
| Employees: | 373 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
First drug granted approval under FDA’s Limited Population Pathway for Antibacterial and Antifungal Drugs (Image: Bronchiectasis News Today)
Gold and other precious metals are heading higher again and cementing their status as an ongoing safe haven in time of volatility. Samaranta Mining Corporation (SAX.TSXV) is doing its best to
| Last Price 17.40 | Change $ 1.28 | Change % 7.94 | Tick N/A |
| Bid 15.90 | Bid Size 100.00 | Ask 38.00 | Ask Size 500.00 |
| Open 16.44 | High 17.66 | Low 16.30 | Prev Close 16.12 |
| Last Trade | Volume 1.3 mi | 52 Wk Hi 33.13 | 52 Wk Low 11.31 |
| Market Cap 1.6 bi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 89,207,638.00 | EPS (TTM) -4.10 | PE Ratio N/A | Exchange NGS |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 11 | 30 |
| Number of Buys | 9 | 19 |
| Number of Sells | 2 | 11 |
| Net Activity | 42462 | 90128 |
| Last 10 Buys | Shares |
|---|---|
| Christine A. Pellizzari | 1,000 |
| Christine A. Pellizzari | 1,000 |
| William Lewis | 1,000 |
| Melvin Sharoky | 1,000 |
| William Lewis | 1,000 |
| William Lewis | 1,000 |
| William Lewis | 1,000 |
| William Lewis | 1,000 |
| William Lewis | 1,000 |
| William Lewis | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| S. Nicole Schaeffer | 1,000 |
| S. Nicole Schaeffer | 1,000 |
| Donald J. Hayden | 1,000 |
| Donald J. Hayden | 1,000 |
| Melvin Sharoky | 1,000 |
| Melvin Sharoky | 1,000 |
| Donald J. Hayden | 1,000 |
| Donald J. Hayden | 1,000 |
| Melvin Sharoky | 1,000 |
| Melvin Sharoky | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 56 | 56 | 56 | 56 |
| Low Target Price Estimate | 35 | 35 | 35 | 35 |
| Mean Target Price Estimate | 41.67 | 41.67 | 41.71 | 41.67 |
| Standard Deviation | 7.53 | 7.53 | 6.87 | 7.53 |
| Date of Most Recent Estimate | 05/07/18 | 05/07/18 | 05/07/18 | 05/07/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| S-8 | Securities offered to employees under employee benefit plans | 11 | 2018-05-31 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-31 |
| 3 | Initial statement of beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-05-17 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 |
| Moderate Buy | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 1.08 | 1.07 | 1.07 | 1 |
© 2019 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
